Remicade News and Research

RSS
Juvenile arthritis affected kids are at a high risk of cancer: Study

Juvenile arthritis affected kids are at a high risk of cancer: Study

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

Anti-TNFs, methotrexate may reduce risk of cardiovascular disease in people with RA

Anti-TNFs, methotrexate may reduce risk of cardiovascular disease in people with RA

Link between use of anti-TNF therapy and malignant melanoma in RA patients

Link between use of anti-TNF therapy and malignant melanoma in RA patients

Doctors may stop anti-TNF medications for RA patients before surgery to reduce disease flares

Doctors may stop anti-TNF medications for RA patients before surgery to reduce disease flares

Merck third quarter global sales increase 8% to $12.0 billion

Merck third quarter global sales increase 8% to $12.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Janssen Biotech receives FDA approval for Remicade to treat UC in children

New report on the immunomodulators market outlook to 2016

New report on the immunomodulators market outlook to 2016

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

NYU Langone webinar discusses advances in the treatment of RA

NYU Langone webinar discusses advances in the treatment of RA

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Healthcare advertising agencies earn Med Ad News recognition

Healthcare advertising agencies earn Med Ad News recognition

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONI

Johnson & Johnson provides further details regarding distribution rights for REMICADE, SIMPONI

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

JNJ, Merck sign distribution agreement for REMICADE and SIMPONI

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment

Decision Resources: 68% of gastroenterologists select Remicade for Crohn's treatment